Smart Mandibular Advancement Device (MAD) for sleep monitoring**

阻塞性睡眠呼吸暂停（OSA）是一种影响3-7%普通人群和40%肥胖患者的疾病。一般来说，诊断睡眠呼吸暂停和确定OSA治疗效果需要在实验室对睡眠期间的呼吸和其他身体功能进行夜间监测。然而，由于加拿大睡眠实验室的能力有限，进行睡眠研究需要很长时间。下颌推进装置（MAD）是一种治疗阻塞性睡眠呼吸暂停的器械。该项目的目的是设计、开发和评估一种具有成本效益的口腔内智能MAD，该MAD集成了多传感器平台和EEG电极。智能MAD将允许口内测量生理参数，如血氧饱和度、脑电图信号、心脏和呼吸频率，以及加速测量，以检测睡眠潜伏期、开始和持续时间。该平台将有可能记录在家中的睡眠模式，并及时评估MAD治疗的有效性。目前市场上还没有智能MADs。为患者提供这样的设备将有助于iMD Research在生产的前24个月内获得魁北克MAD市场份额的10%。由于MAD的生理监测功能，Metropole Dentaire将能够治疗更大比例的OSA患者，预计在最初生产的两年内将翻一番。加拿大的医疗保健提供者将能够定期记录患者的睡眠情况，并评估MAD治疗的有效性，而无需将他们送到睡眠实验室。因此，它将减少对睡眠实验室的大量需求，降低加拿大的治疗成本。记录患者的睡眠数据将有助于促进加拿大的睡眠呼吸暂停研究和治疗。未来，多传感平台和脑电图电极将嵌入到其他口腔内可穿戴设备中，以在家中诊断睡眠呼吸暂停和其他健康状况。这将有助于更快地诊断睡眠呼吸暂停，减少未经治疗的睡眠呼吸暂停患者的数量，从而减少与未经治疗的睡眠呼吸暂停相关的经济损失。此外，这将减少加拿大医疗保健系统对健康状况诊断的等待时间。

Obstructive Sleep Apnea (OSA) is a condition that affects 3-7% of the general population and 40% of patients with obesity. Generally, diagnosis of sleep apnea and determining the efficacy OSA treatment involve overnight monitoring of breathing and other body functions during sleep at labs. However, due to the limited capacity of sleep labs in Canada there is a long waiting to do sleep studies. Mandibular Advancement Device (MAD) is designed to treat OSA. The aim of this project is to design, develop and evaluate a cost effective intraoral smart MAD integrating a multi sensor platform and EEG electrodes. The smart MAD will allow intraoral measurement of physiological parameters such as blood oxygen saturation, EEG signal, heart and breathing rate as well as accelerometry to detect sleep latency, onset and duration. The platform will have potential to document sleep patterns from home and evaluate the effectiveness of MAD treatment on time. There are currently no intelligent MADs on the market. Providing patients with such a device should help iMD Research acquire a projected 10% of Quebec MAD market share within the first 24 months of production. Due to the physiological monitoring feature of the MAD, Metropole Dentaire will be able to treat a much larger portion of the OSA population expected to double within 2 years of initial production. The healthcare providers in Canada will be able to document patient's sleep on a regular basis and evaluate the effectiveness of the MAD treatment without sending them to sleep labs. Thus, it will lower the heavy demand on sleep labs and lower the treatment cost in Canada. Documenting the sleep data on patients will help advance the sleep apnea research and treatment in Canada. In the future, the multi sensing platform and the EEG electrodes will be embedded in other intraoral wearable devices to diagnose sleep apnea and other health conditions from home. This will help diagnose sleep apnea faster and reduce the number of untreated sleep apnea patients, which, in turn, will reduce the economic loss related to untreated sleep apnea. Additionally, this will reduce the wait times in Canadian healthcare system for health condition diagnosis.